Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Luis Gonzaga Paz-Ares
Luis Gonzaga Paz-Ares Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext )


  • María Teresa Agullo
  • Irene Ferrer
  • Eva María Garrido
  • Beatriz Soldevilla

Investigador Clínico I

  • Rocio García
  • Santiago Ponce
  • María del Carmen Riesco
  • José Luis Solórzano
  • Jon Zugazagoitia

Becarios Post-doctorales

  • María Cristina Cirauqui
  • Juan Manuel Coya
  • Raúl Rincón

Becarios Pre-Doctorales

  • Carlos Carretero
  • Santiago García
  • Alberto Lens
  • Ángel Núñez
  • Javier Ramos
  • Beatriz Rubio
  • Alba Santos Ramos
  • Patricia Yagüe

Técnicos de Laboratorio

  • Patricia Cozar
  • Laura García
  • Beatriz Gil
  • Patricia Llamas
  • Alicia Luengo
  • Patricia Plaza
  • Aranzazu Rosado
  • Rocío Suárez

Lung cancer continues to be the most frequent cause of cancer- related deaths worldwide. Our Unit focuses on the study of lung cancer, from fundamental research proposals to other more clinically oriented ones that are closer to solving the problems of lung cancer patients. The two main research areas of our Unit involve : the identification of new molecular biomarkers that can be used in the clinic for diagnostic, prognostic and predictive purposes; and the development of novel treatment strategies that include targeted therapies and immunotherapeutics. For example, we have contributed to elucidating the molecular determinants of EGFR or FGFR oncogenicity and have discovered biomarkers that may guide the efficacy of inhibitors of those receptors in lung cancer. On the other hand, we have developed a patient-derived xenograft (PDX) platform of non-small-cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in taking new drugs to the clinic ( phase I trials ), as well as in conducting practice-changing phase II/III trials in the fields of precision oncology and immuno-oncology.